OTOLARYNGOLOGIC
CLINICS OF
NORTH AMERICA

Otolaryngol Clin N Am
35 (2002) 1365–1388

Cumulative Index 2002

Volume 35

February	OFFICE BASED PROCEDURES IN FACIAL PLASTIC SURGERY, pages 1–226
April	CONTEMPORARY NEUROTOLOGY, pages 227–454
June	PATHOGENESIS OF MENIERE'S DISEASE: TREATMENT CONSIDERATIONS, pages 455–698
August	DIAGNOSIS AND MANAGEMENT OF HEARING LOSS IN INFANTS AND YOUNG CHILDREN, pages 699–952
October	LARYNGEAL MALIGNANCIES: MANAGEMENT AT JOHNS HOPKINS, pages 953–1142
December	COMPUTERS IN OTOLARYNGOLOGY, pages 1143–1388

Note: Page numbers of article titles are in **boldface** type

A

Accutane, skin resurfacing following use of, 63, 144

Ackerman's tumor, 1015

Acoustic immitance measures, in children, 715, 723

Acoustic neuroma(s), and tumors of cerebellopontine angle, 417
- assessment and management of, **395–406**
- audiometric assessment in, 398–399
- background of, 345–346
- bilateral, in neurofibromatosis type 2, 395
- classification of, 395
- diagnostic assessment in, 400
- endoscopy in, 298–303
- epidemiology of, 396
- imaging assessment in, 399–400
- imaging in, 243, 1327, 1328
- management of, 401–404
- natural history of, 400–401
- nonsurgical treatment of, 401–402
- physical findings in, 396–398
- presentation of, 398
- sporadic unilateral, 395
- stereotactic radiosurgery in, 401–402
- surgery in, 402–404
  - hearing preservation in, 419–421
- treatment of, 234–235

Acoustic reflex threshold, measurements of, in children, 716–717

Acoustic tumors, stereotactic radiosurgery in, **345–357**

Acrobot, 1309

Adipose grafts, for augmentation of lips, 96–97

Advertising, on billboard, 1150, 1151
- Web-based, 1151–1153

AESOP, 1309–1310, 1311

Allergy, and Ménière's disease, 480, 536–537, 582–583

Alloderm, for augmentation of lips, 97–98
- micronized, for soft tissue augmentation, 81–82

Alloplastic implants, for soft tissue augmentation, 82–83

Alport syndrome, hearing loss in, 825–826

Aluminum crystals, toxicity of, during microepidermabrasion, 148–149

Aminoglycosides, for chemical labyrinthetomy, 676, 677
- ototoxicity of, 676

Anesthesia, for augmentation of lips, 93–94

0030-6665/02/S - see front matter © 2002, Elsevier Science (USA). All rights reserved.
PII: S0030-6665(02)00113-5

Anesthetics, general, for facial plastic procedures, 29–30
local, alkalinization of, 44–45
allergic reactions to, 48–50
classification of, 34–35
considerations for use of, 50–51
eutectic mixture of, 38–39
for facial plastic procedures, **29–53**
advantages of, 30
informed consent for, 31
limitations of, 29
medical and surgical history for, 31–32
perioperative considerations for, 32–33
preoperative preparation for, 30–31
for subcutaneous infiltration, 40–42
for topical use, 37–39
history of use of, 33
ideal, properties of, 37
mechanism of action of, 33–34
onset potency and duration of action of, 35–36
pharmacodynamics of, 34–37
systemic reactions to, 45–48
toxicity of, and adverse reactions to, 45–50
vasoconstrictors added to, 43–44

Antibiotics, perioperative, in mastoidectomy, 921

Antihistamines, in Ménière's disease, 584, 587

Arachnoid cysts, of cerebellopontine angle, imaging of, 245, 1330, 1331

Artecoll, for soft tissue augmentation, 83, 96

Atresiaplasty, in auricular atresia, 883–884

Atticotomy, definition of, 912
technique of, 915

Audiology, in pediatric hearing loss, 733
neuro-otology and, 230–231

Audiometry, conditional play, with reinforcement in children, 719
glycerol test with, in Ménière's disease, 557
in evaluation of dizziness, 263
in Ménière's disease, 290, 549–550, 551
visual reinforcement, with reinforcement in children, 718–719

Auditory brainstem implant, device design for, 338, 339
in acoustic neuroma resection, 301–303
indications for, 337
patient selection for, 337
surgery for, complications of, 340–341
rehabilitation following, 341
results of, 341
technique of, 338–340

Auditory brainstem response, assessment of, using tone bursts, 709–710
bone-conduction, 710–711
click-evoked, assessment of, in children, 708–709, 721
in Ménière's disease, 551–554
testing of, in children, 708

Auditory canal, external, imaging of, 251–252, 1362–1363
internal, imaging of, 1326–1335
strategies for, 242–245
middle fossa approach to, 383–385

Auditory processing disorder(s), and recurrent otitis media, 927–928
assessment and diagnosis of, 928–931
clinical profile in, 928
comorbidity in, 927–928
definition of, 925
etiology of, 926
in children, assessment in non-native English speakers, 931
assessment of, 930–931
auditory training in, 934
computer-mediated therapy in, 936
deciphering of, **925–942**
differential diagnosis of, 931–933
metalinguistic and metacognitive strategies in, 934
testing and medication in, 933, 935
interaction with peripheral hearing loss, 930
prevalence of, 926–927
screening for, 932
treatment and management approaches in, 933–936

Auricular atresia, congenital, clinical manifestations of, 881
diagnosis of, 881
grading system for, 882–883
initial evaluation in, 880
options for intervention and timing of repair, **879–892**
presentation of, 880–881
surgical management of, 883–884

anesthesia for, 887
approach for, 885–887
complications of, 891
goal of, 884
postoperative care in, 890–891
risks of, 884–885
skin graft for, 888–890
technique of, 885

Autoimmune inner ear disease, and sudden deafness, MicroWick in, 648
microcatheter for, 649
MicroWick for, 650–651
transtympanic injections for, 649

Autoimmunity tests, in Ménière's disease, 559

Autologen, 77, 95–96

B

Behavioral assessment of hearing, with reinforcement in children, 718

Bell's palsy, 359–362
imaging in, 246–247, 1338

Binoculars, virtual, 1285, 1286

Biologic implants, 74–82

Bioplastique, for augmentation of lips, 98–99
for soft tissue augmentation, 82–83

Biopsy, skin. See *Skin biopsy*.

Blepharoplasty, transconjunctival, for laser skin resurfacing, 131

Blom-Singer voice prosthesis, following total laryngectomy, 1075

Blood supply, cerebral, 413

Boolean search techniques, 1170–1171

Botox, 172

Botulinum toxin, commercial types of, 172–173
handling and storage of, 172
history of use of, 171
in facial plastic surgery, **171–186**
adjunctive usage of, 183
anatomy of face and, 174, 175
complications and contraindications to, 183–185
of eyebrow, 177
of glabella, 174–175, 176
of middle third of face, 177–179
of nasal bridge, 175–176
of upper third of face and forehead, 173–177
injection of, electromyographic guidance for, 173
technique for, 173
techniques for use of, 171–172
type A, 172
with laser skin resurfacing, 131

Bovie, in neuro-otology, 231

Bovine collagen, 74–77, 95

Brain, functional imaging of, 242

Brainstem, cochlear implants and, **325–343**

Branchio-Oto-Renal syndrome, hearing loss in, 826

Brow, incisionless reanimation surgery of, 439–443

Bupivacaine, 41–42

C

Caloric testing, in children, 769

Canal wall-down tympanomastoidectomy, 372, 373

Canal wall-up tympanomastoidectomy, 372, 373

Cancer, development of, human papillomavirus and, 986
of larynx. See *Laryngeal cancer*.

Carbon dioxide laser, for keloid excision, 213, 214
pulsed, 120–121
and Er:YAG laser, combined, 123
in sequence, 123–124
for skin resurfacing, technique of, 126–127

Carboplatin, 5-fluorouracil, and radiotherapy, in oropharyngeal cancer, 1038

Carcinoma, squamous, of larynx, definitive radiotherapy for, **1003–1023**
squamous cell, of head and neck, genetic alterations in, 984
trials of chemoradiotherapy in, 1035

Cardiac surgery, robotic, 1311–1312

Cardiovascular system, toxicity of local anesthetics to, 47

Carotid aneurysms, petrous, imaging of, 1346, 1347

Carotid artery, aberrant, 1353
in skull base tumors, 413–414

Central auditory processing disorder. See *Auditory processing disorder(s)*.

Central nervous system, toxicity of local anesthetics to, 46

Cerebellopontine angle, epidermoids of,
imaging of, 244–245, 1331, 1332
imaging of, 1326–1335
strategies for, 242–245
lipomas of, imaging of, 1331, 1332
tumors of, acoustic neuroma and, 417

Cerebral blood supply, 413

Cerebrospinal fluid leaks, of temporal bone, imaging in, 247, 1340, 1341, 1342–1343

Cervical cutaneous flaps, following laryngopharyngectomy, 1093

Chemical peels, background of, 55–56
classification of, 56–57
indications for, 58–59
patient selection for, 58–59
specific, 61–71
update on, **55–72**

Chemoradiotherapy, and radiotherapy, for laryngeal cancer, 1010–1014
in laryngeal preservation, 1031–1032
trials of, in squamous cell carcinoma of head and neck, 1035

Chemotherapy, and radiation therapy, sequential, in laryngeal cancer, 1072
induction, in laryngeal preservation strategies, 1029–1032

Child(ren), and infants, hearing loss in, otolaryngologist in management of, **743–754**
audiologic assessment in, goals of, 707
auditory processing disorders in, deciphering of, **925–942**
cholesteatoma in, management of, **809–819**
hearing loss, medical evaluation of, **729–742**
otitis media in, medical and surgical management of, **793–807**
sensorineural fluctuating hearing loss in, **839–853**
with suspected hearing loss, audiologic assessment of, **707–728**
young, cochlear implants in, **893–910**
evaluation of vestibular function in, **755–780**

Cholesteatoma, and surgical failure in chronic ear disease, 913
endoscopes during surgery of, 315–316
pediatric, acquired, 811
classification and pathophysiology of, 810–813
congenital, 811–813
evaluation of, 813–814
incidence and problems of, 810
management of, **809–819**
goals for, 809
programs and special considerations in, 816–817
studies of, 809–810
surgery for, 814–816
vertigo in, 268

Cholesterol granuloma, 316–317, 1343, 1344
endoscopes during surgery of, 317

Chordoma, endoscopes during surgery of, 314–315
of petrous apex, imaging of, 1346, 1348–1349

Cisplatin, and 5-fluorouracil, in cancer of head and neck, 1036–1037
in laryngeal preservation, 1029–1031
in squamous cell carcinoma of head and neck, 1036

Clinical database(s), "bare minimum," 1247, 1248
creation of, considerations for, 1246
data field and entry form design considerations for, 1258–1261
data point subgroupings of, business rules and, 1256
data points in, selection of, 1254–1255
designing of, **1245–1262**
development platform, selection of, 1252–1254
field type(s), and entry form methodology, choosing of, 1258–1260
and "not done" item, 1260–1261
"not done" value and, 1255–1256
persons needing, 1246–1247
record identification and, 1257, 1258
relational, "normalization" in, 1251–1257
relational structures versus flat-file structures in, 1247–1250
security for, 1261
structure of, laying out of, 1257
universal fields and, 1258

Clinical Queries, of PubMed, 1171

Cocaine, 37–38

COCH gene, and inherited Ménière's disease, 508–512, 513, 533

Cochlear implants, and brainstem implantation, **325–343**

audiologic assessment for, 333–334
basic components of, 326, 327
electrical testing for, 334
electrode design for, 326–328, 329, 330, 331
in bilateral sensorineural hearing loss, 325
in profound sensorineural hearing loss, 236–237
in young children, **893–910**
age for, 894–895
history of, 893–894
in chronic otitis media, 906
indications for, 894
malformations and, 896, 906
ossification and, 896–897, 906
severity of hearing loss and, 895–896
surgery for, 905–906
future directions in, 907–908
outcomes of, 906–907
medical evaluation for, 332–333
patient selection for, 330–332
preoperative imaging for, 334
rehabilitation following, 336
speech-coding strategies and speech processors for, 328–330, 332
surgery for, complications of, 335–336
results of, 336–337
technique of, 334–335
technology of, 897–904
advanced Bionics Clarion, 899–900
Cochlear Corporation Nucleus-24, 900
external device components, 899
internal device components, 897–898
magnets and magnetic resonance imaging, 902
MedEl Combi 40+, 900–901
special electrode arrays, 901
speech-processing strategies of, 903–904
speech processor features of, 902–903
stimulation modes, 898
telemetry for, 330

Cochlear nerve(s), 659
and Ménière's disease, 520
trigeminal, facial, or vestibular nerves, endoscopy in surgery of, 303–309

Cochleovestibular cleavage plane, 659

Cochrane Library medical database, 1166

Collagen, allogenic, 77–78
and injectable fillers, **73–85**
autologous, 77
bovine, 74–77, 95

Collagen implants, for augmentation of lips, 95–96

Colon segment interposition, following laryngopharyngectomy, 1097

Compere, Gene, 229

Computed tomography, high-resolution, 246, 1319–1320
in laryngeal cancer, 961, 967, 971–972
technique of, 962
prior to laryngopharyngectomy, 1089
single photon emission, 239

Computerized medical record, 1211

Computerized physician-order entry, **1237–1244**
barriers to implementation of, 1241–1242
cost savings associated with, 1241
error reduction and, 1240–1241
overview of, 1238
rationale for, 1238–1240

Cranial defect, reconstruction of, following lateral skull base surgery, 443–445

Cranial nerves, posterior fossa exposure of, 658
schwannomas of, imaging of, 244, 1329–1331
seventh and eighth, anatomy of, 658

Craniotomy, middle fossa, 383, 384–385

Crow's feet, orbicularis and, botulinum toxin injection in, 178–179

Cryogens, minimum temperatures of, 154

Cryosurgery, for removal of skin lesions, 153–156
lesions treated with, 157
tissue destruction after, 156

Cubby, of PubMed, 1172

Curettage and electrodesiccation, for removal of skin lesions, 163–166

Cyanoacrylate tissue adhesives, butyl-2-cyanoacrylate, 104–105
chemical composition of, 104
for skin closure in outpatient setting, **103–118**
history of, 104
octyl-2-cyanoacrylate. See *Octyl-2-cyanoacrylate*.

CyberKnife, 1306–1308

Cymetra, for soft tissue augmentation, 81

Cytomegalovirus, hearing loss caused by, 747

D

Dark cells, and Ménière's disease, 520–521, 522

Databases, clinical. See *Clinical database(s)*.

daVinci Surgical System, 1304–1305, 1307, 1311

Deafness, sudden, and autoimmune inner ear disease, Microwick for perfusion of inner ear in, 648
- microcatheter for, 649
- MicroWick for, 650–651
- transtympanic injections for, 649

Deltopectoral fasciocutaneous flap, pedicled, following laryngopharyngectomy, 1094

Dermabond. See *Cyanoacrylate tissue adhesives*.

Dermabrasion, 56, 119

Dermalogen, 77–78

Diagnostic imaging, **1319–1365**

Diamond-tipped appliances, for microepidermabrasion, 150

Digital camera, accessories for, and power of, 1183–1185
- background of, 1175–1176
- basics of, 1176–1179
- image files and, 1179–1182, 1183
- in clinical practice, **1175–1188**
- medical uses of, 1185–1188

Digital image archiving, **1191–1202**
- file backup in, 1193–1194
- organizing and finding photographic files in, 1195–1201
- photoediting options in, 1202
- physical location of images for, 1192
- requirements for, 1192
- viewing thumbnails in, 1193

Dissection simulator, temporal bone, 1285, 1286

Distortion-product otoacoustic emissions, glycerol test with, in Ménière's disease, 557–558

Diuretics, in Ménière's disease, 585, 587

Dizziness, assessment and management of, **255–273**
- differential diagnosis of, 264–267
- evaluation of, audiometry in, 263
  - blood tests in, 258
  - computerized dynamic posturography in, 261–263
  - electronystagmography in, 258–261
  - medical history in, 255–256
  - physical examination in, 257
  - radiography in, 263–264
  - rotational testing in, 261
- nonsystematized, in central nervous system tumors, 266
  - in cerebral anoxia, 265
  - in epilepsy, 267
  - in infection, 265–266
  - in metabolic abnormalities, 266–267
  - in migraines, 267
  - in ocular abnormalities, 265
  - in proprioceptive system abnormalities, 264
  - in trauma, 266

Docetaxel, trials of, in laryngeal preservation, 1031–1032

Drills, otologic, in neuro-otology, 232

Dysphagia, 1102–1103

Dysport, 172–173

E

Ear, disease of, chronic, 911
- clinical presentation of, 911
- preoperative considerations in, 914
- surgery for, goals of, 913
- surgical technique in, 915
- chronic complicated, imaging of, 1359
- inner, autoimmune disease of. See *Autoimmune inner ear disease*.
  - chemical perfusion of, **639–653**
    - complications of, 651
    - historical perspective on, 640
    - injection onto material in round window niche, 643
    - microcatheter sustained delivery for, 643–645
    - MicroWick in, for sustained delivery, 645–648
    - results of, 648–651
    - transtympanic injections in, 642–643

treatment concepts in, 640–642
immune-mediated disease of, Ménière's disease and, 583–584
middle. See *Middle ear.*

Ear canal volume, equivalent, in children, 716

Ear disease, chronic, complicated, imaging in, 251

Earlobe, piercing of, local complications of, 188
torn, causes of, 187–188
classification of, 188–189
prevalence of, 188
reconstruction of, 202–204
repair of, **187–205**
general recommendations for, 199–202
guidelines and technical steps in, 200–201
repiercing following, 201–202
technique(s) of, 189–199
hole preservation with inferior rim modification, 195–199
hole preservation with straight-line closure, 190–191, 192
straight-line closure, 189
straight-line closure with inferior rim modification, 191–195

Earmolds, for children, 786–787

Ectropion, of lower eyelid, following phenol peel, 70

Electro-oculography, in children, 760–761

Electrocochleography, and glycerol test, in Ménière's disease, 557
in Ménière's disease, 290, 552, 554–556, 630

Electrodesiccation, curettage and, for removal of skin lesions, 163–166

Electrolarynx, and tracheoesophageal puncture, compared, following total laryngectomy, 1076
following total laryngectomy, 1073, 1074

Electromyography, for guidance of injection of botulinum toxin, 173

Electronic medical record. See *Medical record, electronic.*

Electronystagmography, in evaluation of dizziness, 258–261
standard, in children, 768–769, 770–771

Ellipse, for removal of skin lesions, 166–167

EMBASE, of Exerpta Medica, 1166

Endolymphatic duct and sac, 523–524

Endolymphatic hydrops, 531
and Ménière's disease, 455, 472, 473, 517–519, 531–532, 566, 573–575, 622
vertigo in, 269–272

Endolymphatic sac, 466, 479–480

Endolymphatic sac surgery, **591–606**
and surgery for chronic otitis media, 596–597
complications of, 636
early treatment using, 604–605
experience with, panel discussion on, 626–627
for reversal of pathogenesis of Ménière's disease, **621–637**
history of, 621–622
in progressive Ménière's disease, 625–626
indications for, 627–629
intraoperative electrocochleographic monitoring and, 595–596
method of, 631–635
pathophysiologic basis of, evidence for, 595–599
placebo effect controversy and, 592–595
postoperative care following, 635
preoperative evaluation and counseling for, 629–631
results of, 635–636
endolymph seepage and hearing/fullness and, 599
for American Academy of Otolaryngology 1972 class A patients, 597–599
revision of, altered blood supply and, 619
case reports of, 610–615
clinical implications of, 617–618
decompression in, 619
for recurrent Ménière's disease, 541–542, **607–619**
modifications used in, 615–617
natural and "induced" Ménière's disease and, 618–619

Endolymphatic sac surgery (*continued*)
osmotic pull in, 619
passive diffusion of endolymph and, 619
selection of patients for, 627–629
success of, keys to, 600–605
theoretic rationale for, 599–600

Endolymphatic system, anatomy and physiology of, 465–467

Endoscopic Sinus Surgery Simulator, development and evaluation of, 1290
in example of assessment of errors, **1289–1301**
metrics for errors in, 1298–1299
outcomes measures and, 1299, 1300
taxonomy of errors and, 1296, 1297

Endoscopic vestibular neurectomy, 304–308
advantages and limitations of, 308–309

Endoscopy, in acoustic neuromas, 298–303
in neuro-otologic surgery, **297–323**
in surgery of lateral skull base, 313–318
in surgery of trigeminal, facial, cochlear or vestibular nerves, 303–309

ENTLink, 1155–1157

Epidermal growth factor, in laryngeal cancer, 990

Epidermal growth factor receptor, in head and neck cancer, 1038

Epidermoids, endoscopes during surgery of, 315–316
of cerebellopontine angle, imaging of, 244–245, 1331, 1332

Epinephrine, added to local anesthetics, 43–44

Epitympanum, development of, 857

Erbium:YAG laser, 121–123
and pulsed carbon dioxide laser, combined, 123
for laser skin resurfacing, 120–131
in sequence, 123–124
for skin resurfacing, technique of, 127–128

Erythema, following laser skin resurfacing, 129
following phenol peel, 69–70

Esophageal speech, and tracheoesophageal puncture, compared, following total laryngectomy, 1075–1076
following total laryngectomy, 1073–1074

Eustachian tube, anatomy of, 699–700
as part of system, 699
function of, 701–704
physiology of, 700–701
update on, **699–705**

Exerpta Medica, EMBASE of, 1166

Eyelid, lower, incisionless reanimation surgery of, 437–439

F

Face, incisionless reanimation surgery of, 435–443
lateral skull base surgery with, reconstruction following, **427–446**
surgical technique for, 436
lower third of, anatomy of, 179–180
middle third of, anatomy of, 177–178
plastic surgery of, local anesthetics for. See Anesthetics, local, for facial plastic procedures.
office-based procedures in, **1–220**

Facial canal, development of, 857–858

Facial nerve, 660
imaging of, 245–246, 1335–1340
postoperative function of, assessment of, 417–418
preservation of, in skull base surgery, 417–418
reconstruction of, in lateral skull base surgery, 434–435
schwannomas of, imaging of, 244, 1336–1338
trigeminal, cochlear, or vestibular nerves, endoscopy in surgery of, 303–309

Facial neuroma, 1325

Facial paralysis, **359–367**
causes of, 359, 360
iatrogenic, 364–366
idiopathic, 359–363
in facial nerve injury, management of, 365–366
trauma causing, 363–364

Fascia grafts, for augmentation of lips, 97

Fascia lata, preserved particulate, for soft tissue augmentation, 81

Fat injection, autologous, for soft tissue augmentation, 78–79

Fibrel, for soft tissue augmentation, 79–80

Fibrin tissue adhesives, application of, 116
as sealant, 114
autologous, attempts to create, 114–116
uses of, 117

Fibroblasts, autologous, for soft tissue injection, 78

Field cancerization, and laryngeal cancer, 991–993

Fitzpatrick skin classification system, 59

Fitzpatrick's sun-reactive skin types, 124–125

Flaps, in reconstruction of lateral skull base, 427–431

5-Fluorouracil, and cisplatin, in cancer of head and neck, 1036–1037
carboplatin, and radiotherapy, in oropharyngeal cancer, 1038
trials of, in laryngeal preservation, 1037

Free-text search, 1169–1170

Free tissue transfer, following laryngopharyngectomy, 1094

G

Gamma knife. See *Stereotactic radiosurgery*.

Gastric pull-up, following laryngopharyngectomy, 1096–1097

Gastro-omental free flap, following laryngopharyngectomy, 1096

Gelatin matrix implant, for soft tissue augmentation, 79–80

General surgery, robotic, 1309–1311

Genes, in hearing loss. See under Hearing loss.

Genetic progression model, in laryngeal cancer, 990–991

Genetic testing, in pediatric hearing loss, 737–739

Genetics, alterations of, in squamous cell carcinoma of head and neck, 984
in laryngeal cancer, 946, 984–985
Ménière's disease and, **497–516**, 535

Gentamicin, for chemical labyrinthetomy, 677, 680–681
transtympanic perfusion of, in Meniere's disease, **287–295**

Glogau skin classification system, 59, 60

Glomus jugulare lesions, 235
imaging of, 1347, 1354–1356
treatment of, 235–236

Glomus tympanicum tumors, 235
treatment of, 235–236

Glottic cancer. See *Laryngeal cancer, glottic*.

Glucose tolerance test, and plasma insulin measurement, in Ménière's disease, 559

Glycerol test, and electrocochleography, in Ménière's disease, 557
with audiometry, in Ménière's disease, 557
with distortion-product otoacoustic emissions, in Ménière's disease, 557–558

Gore-Tex, for augmentation of lips, 99

Gynecologic surgery, robotic, 1309, 1310–1311

H

Head and neck, cancer(s) of, environmental exposure and, 985–986
epidermal growth factor receptor in, 1038–1039
robotic surgery of, 1308
squamous cell carcinoma of, genetic alterations in, 984
trials of chemoradiotherapy in, 1035

Headlight, in neuro-otology, 231

Health care, information paradigm, motivation behind, 1223–1226

Health information system, of hospital. See *Hospital, health information system of*.

Health Insurance Portability and Accountability Act of 1996, 1204–1209, 1224
compliance with, 1225–1226
privacy standards and, 1225
standard transactions and, 1261–1262

Health Level Seven, 1218

Hearing, preservation of, in acoustic neuroma surgery, 419–421

Hearing aid(s), adjustment of output of, in infants and children, 785–786
body-style, for children, 784–785
bone-anchored, in auricular atresia, 883

Hearing aid(s) (*continued*)
in children, in congenital middle ear anomalies, 871–874
results of, 873–874
surgical technology for, 872–873
brand of, selection of, for infants and children, 785
features of, selection of, for children, 783–784
fitting of, on infants and children, **781–791**
ear-specific measurements for, 782–783
frequency-specific measurements for, 782–783
for infants and children, counseling parents on, 788
keeping in place, in infants and children, 787
managing feedback of, in infants and children, 787–788
monoaural versus biaural fitting, on infants and children, 785

Hearing devices, surgically implanted, in moderate sensorineural hearing loss, 237

Hearing loss, and homeostasis, genes in, 831
and vestibular loss, in young children, 756
classification of, 275–276
conductive, 748–749
in children, bone-anchored hearing aid in, 871–874
embryology of, 856–858
epidemiology of, 855–856
evaluation of, 858–859
in congenital anomalies, 860–871
surgical approach in, 859–860
surgical management of, **855–877**
epidemiology of, 822
genes and, 829–833
implications of, 282–283
genes encoding extracellular matrix components and, 281–282
genes encoding membrane components and, 280–281
genes encoding transcriptional regulatory proteins and, 282
hair cell-structure genes and, 831–832
hereditary, **275–285**
gene identification in, 276–279
hereditary sensorineural, 748
in infants and children, family history in, 744
initial evaluation in, 744–746
laboratory evaluation in, 746–747
otolaryngologist in management of, **743–754**
perinatal history in, 745
physical examination in, 745–746
prenatal history in, 744–745
radiologic studies in, 747–748
in Meniere's disease, 288
in young children, severity of, cochlear implants and, 895–896
in young infants, detection and characterization of, 839–841
mitochondrial genes and, 282, 833
molecules encoding cytoskeletal components and, 281
nonsyndromic, 828–829
auditive genes and, 829–833
pediatric, acquired versus hereditary, incidence of, 729–730
auditory in, 733
classification of, 730
electrocardiogram in, 735
endocrine function assessment in, 734
family history in, 732
genetic testing in, 737–739
hematology and biochemistry in, 733–734
immunology in, 734
laboratory testing in, 733
medical evaluation of, **729–742**
metabolic screen in, 735
perinatal history in, 731
physical examination in, 732–739
postnatal history in, 732
prenatal history in, 730–731
radiology in, 735–737
urinalysis in, 735
peripheral, interaction with auditory processing disorders, 930
sensorineural, moderate, surgically implanted hearing devices in, 237
profound, 236
cochlear implants in, 236–237
syndromic and nonsyndromic, etiology of, **821–838**
sensorineural fluctuating, in children, **839–853**
auditory threshold variation patterns in, 845–851
behavioral auditory thresholds and, 843–844
etiologic considerations in, 844–845
studies of, 821–822
suspected, children with, audiologic

assessment of, **707–728**
behavioral measures in, 717–720
cross-check principle and, 720–724
physiologic measures in, 708–717
syndromic, 822–828
transcription factors and, 832

Hearing screening, for newborns, 743, 749–751

Hemifacial spasm, microvascular decompression for, 310–313

Herpes zoster oticus, 362–363

Histiocytosis X, endoscopy in management of, 317–318, 319

HLA antigens, and Ménière's disease, 504–505, 533

Hospital, health information system of, 1203
privacy and, 1203–1204
security and, 1202–1203

House, William F., 228–229, 232, 236–237

Hyalform, for soft tissue augmentation, 80, 94

Hyaluronic acid derivatives, for soft tissue augmentation, 80–81, 94–95

Hydrocolloid dressing, for treatment of keloid, 217–218

a-Hydroxy acids, for skin resurfacing, 60–61

Hyperpigmentation, following laser skin resurfacing, 129–130
following phenol peel, 70
following trichloroacetic acid peel, 64

Hypertrophic scars, and keloid, clinical differentiation of, 208

Hypopharyngeal cancers, conservation surgery for, 1091
laryngopharyngectomy in, 1089
metastasis of, 1088
radiotherapy and, 1088–1089
treatment of, 1088

I

Imaging, diagnostic, **1319–1365**
general principles of, 1319–1320
strategies for, 1326–1363

Incus, development of, 856

Infants, and children, hearing loss in, otolaryngologist in management of, **743–754**
hard-of-hearing, family-centered management of, 788–789
hearing screening for, 743, 749–751
young, hearing loss in, detection and characterization of, 839–841

Infection, following laser skin resurfacing, 130
following phenol peel, 70

"Intelligent tutor" module, to identify landmark structures, 1285–1286, 1287

Interferon, for treatment of keloid, 217

Internet, improving searches on, 1172–1173
legal and ethical pitfalls of, 1161
marketing of practice on, **1149–1161**
medical literature on, searching of, **1163–1174**
physician-patient relationship and, **1143–1148**
resources for physician, 1146–1147
search techniques and, 1167–1172
traditional patient encounters with, 1144–1145

Intracanalicular tumors, imaging of, 242–243

Isolagen, 78

Isotretinoin, skin resurfacing following use of, 63, 144

J

Jejunal free flap, following laryngopharyngectomy, 1095

Jervell-Lange-Nielsen syndrome, hearing loss in, 827

Jugular bulb, high, in Ménière's disease, 525

Jugular foramen, imaging of, 249–250, 1347, 1350–1351, 1352
skull base tumors involving, 415–416

K

Keloid, and hypertrophic scars, clinical differentiation of, 208
cause of, 208–209
clinical manifestations of, 210
definition of, 207
epidemiology of, 208
pathogenesis of, 209–210
treatment of, **207–220**
excision alone for, 211–213

Keloid, (*continued*)
hydrocolloid dressing for, 217–218
interferon for, 217
intralesional steroids for, 214–215
laser excision in, 213–214
options for, 210–218
pressure therapy for, 216–217
radiation therapy for, 215–216
recurrence of, 207
shotgun approach to, 218

L

Labyrinth, imaging of, 251, 1356–1361

Labyrinthectomy, chemical, 676–679
and physical, for Ménière's disease, **675–683**
medications for, 677
dose and frequency of administration of, 678
mode of administration of, 677–678
results of, 678–679
physical, 679–680
surgical, 676
transmastoid, 679–680, 681

Labyrinthine concussion, 266

Labyrinthine membrane, ruptures of, in Ménière's disease, 519–520

Labyrinthine schwannoma, imaging of, 1359

Labyrinthitis ossificans, 1323–1324

Langerhans' cell histiocytosis, endoscopy in management of, 317–318, 319

Laryngeal cancer, cytogenetic alterations and, 987
diagnostic assessment of, **943–959**
environmental exposure and, 985–986
evaluation of, 1047–1048
examination of neck in, 948
field cancerization and, 991–993
genetic alterations in, 984–985
genetic progression model in, 990–991
genetics and, 946
glottic, 945, 974–978
early, minimally invasive techniques in, **1045–1056**
radiotherapy for, 1005–1009
side effects of, 1016
types of compared, 1018, 1019–1020
surgical options in, 1048–1050
transoral resection using powered instruments, 1050–1051, 1052
treatment of, selection of, 1053–1054
late-stage, radiotherapy and chemoradiotherapy for, 1010–1014
radiotherapy for, and chemoradiotherapy for, 1010–1014
histology in, 954–955
laryngeal preservation surgery for, **1057–1070**
general medical evaluation for, 1061
head and neck evaluation for, 1059–1061
open-organ, 1061–1067
patient selection for, 1057–1058, 1059, 1061
principles of, 1057–1059
T staging system and, 1059
laryngoscopy in, 949–950
mechanisms underlying, 983–984
metastatic work-up in, 951
molecular biology of, **983–1002**
molecular diagnosis in, 953
molecular diagnostics in, 993–995
novel therapy in, 995–997
of squamous cell origin, staging of, anterior commissure involvement and, 1046–1047
carcinoma in situ, 1046
molecular characterization and, 1047
motion impairment and, 1047
T1 carcinoma in situ, 1046
office evaluation in, 945
operative assessment in, 951–955
organ preservation trials for, **1025–1044**
using chemoradiotherapy, 1033–1035
physical examination in, 948–949
protein-based alterations in, 989–990
proto-oncogene amplification in, 989
radiographic imaging in, 950–951, **961–982**
risk factors for, 945–946
sequential chemotherapy and radiation therapy in, 1072
staging of, 953–954, 1005–1006
and predictive factors in, 979
subglottic, 945, 978–979, 1004–1005
radiotherapy in, 1014–1015
supraglottic, 945, 973–974, 1003–1004
early-stage, radiotherapy for,

1009–1010
late-stage, radiotherapy for, and chemoradiotherapy for, 1010–1014
types of compared, 1018–1019
spread of, 949
swallowing and speech therapy after, **1101–1119**
symptoms of, 955–956
TNM staging of, 957–959
transglottic, spread of, 949
treatment of, assessment of general condition for, 948
follow-up after, 955–956
tumor suppressor gene inactivation and allelic loss in, 987–989
types of, 973–979

Laryngeal preservation strategies,
evaluation of, 1026
induction chemotherapy in, 1029–1032
nonsurgical, 1072
radiotherapy in, 1026–1029
swallowing following, 1113
swallowing therapy following, 1113–1114
trials of, in laryngeal cancer, **1025–1044**
using chemoradiotherapy, 1033–1035
types of, 1026
voice deficits following, 1112–1113, 1113
voice therapy following, 1113

Laryngeal preservation surgery, for laryngeal cancer, **1057–1070**

Laryngectomy, extended partial, 1072
extended total, for pyriform sinus tumors, 1092
near-total, 1072–1073, 1074
patients following, camaraderie among, 1073
supracricoid, in laryngeal cancer, 1064–1067, 1072
contraindications to, 1065
surgical indications for, 1065
surgical resection in, reconstruction following, 1066–1067
steps in, 1065–1066
supraglottic, in laryngeal cancer, 1062–1064
advantages of, 1064
contraindications to, 1062
surgical resection steps to, 1063–1064
total, Blom-Singer voice prosthesis following, 1075
electrolarynx following, 1073, 1074
and tracheoesophageal puncture compared, 1076
esophageal speech following, 1073–1074
mucosal shunt procedures following, 1074
patient choice of and opinions on, 1071–1072
patient future following, 1073
voice restoration following, history of, 1073–1075
with tracheoesophageal conduit, **1071–1086**
quality of life following, 1083–1085
swallowing following, 1109–1110
voice deficits in, 1107–1108
voice therapy following, 1108–1109
vertical partial, in laryngeal cancer, 1061–1062

Laryngology, nasopharyngoscopy and, efficacy of telemedicine in, 1271–1272

Laryngopharyngectomy, in hypopharyngeal cancers, 1089
indications for, 1088–1089
near-total, 1091
partial, for medial pyriform sinus tumors, 1091
preoperative diagnostic assessment for, 1089–1090
techniques of, 1090–1091
total, 1091
with esophagectomy, 1092
with reconstruction, **1087–1100**
complications of, 1097–1098
history of, 1087–1088
reconstruction techniques for, 1092–1097

Laryngoscope, flexible fiberoptic, 950

Laryngoscopy, direct, 951–952
indirect mirror, 949
rigid 90 degree, 949
rigid fiberoptic, 949

Larynx, anatomic division of, 944, 1003
anatomy of, 946–947, 962, 963–966
cricoarytenoid unit of, 1058
organ preservation surgery and, 1058–1059
glottic, 944
nonsurgical organ preservation strategies for, 1072

Larynx, anatomic (*continued*)
preservation of, in cancers. See *Laryngeal preservation strategies.*
radiographic appearance of, 962–966
reconstruction of,
laryngopharyngectomy with, **1087–1100**
squamous carcinoma of, advanced,
organ preservation for, 1025–1026
definitive radiotherapy for, **1003–1023**
subglottic, 944–945
tumors of. See Laryngeal cancer, subglottic.
supraglottic, 944, 1003–1004
tumors of. See Laryngeal cancer, supraglottic.

Laser(s), for excision of keloid, 213–214
for laser skin resurfacing, 119–124

Laser skin resurfacing, **119–132**
laser wavelengths for, 119
lasers for, 119–124
pulsed carbon dioxide laser for, and
Er:YAG laser for, combined, 123
compared, 120
general considerations for, 125–126
in sequence, 123–124, 128
postprocedure measures in, 128–129
preprocedure measures for, 124–125
problems associated with, 129–131
rhytidectomy in, 131
transconjunctival blepharoplasty for, 131
with botulinum toxin type A, 131

Latissimus dorsi flap, following laryngopharyngectomy, 1094

Lempert, Jules, 227–228, 231

Lidocaine, 40–41

LinkOut, of PubMed, 1171–1172

Lipomas, of cerebellopontine angle, imaging of, 245, 1331, 1333

Lip(s), appearance of, anatomic components influencing, 88–92
augmentation of, adipose and fascia grafts for, 96–98
anesthesia for, 93–94
artificial implantation material for, 98–100
enhancement of, and implantation procedures for, **87–102**
implantable biologic materials for, 94–96
implantable material for, 93
patient evaluation for, 92
surgical management of, 92–93
upper, rhytids of, botulinum toxin injection in, 180

Literature, medical, on Internet, searching of, **1163–1174**
searches of, available sources of, 1165–1167
quality of, 1164

Logical Observation Identifier Names and Codes, 1218

Lymph nodes, cervical, evaluation of, in laryngeal cancer, 967

M

Magnetic resonance imaging, 1319–1320
functional, 1326
high-resolution, 239, 1321–1326
technology update on, 241–242
in laryngeal cancer, 961, 964, 967–971
technique of, 962
magnets, and cochlear implants, 902

Malleus, development of, 856

Master-slave telemanipulators, 1304–1305, 1306, 1307, 1308
cost of, 1313
exposure with, 1312–1313
field of view with, 1312
in telemedicine, 1315
performance with experience, 1313
potential advantages of, 1314–1315
safety issues associated with, 1313–1314

Mastoid, in Ménière's disease, 554

Mastoidectomy, 371–373
canal-wall-down, advantages of, 919–920
definition of, 912
failure of, causes of, 920–921
indications for, 920
intact-canal-wall, advantages of, 920
anesthesia for, 916
definition of, 912
technique of, 916–919
modified radical, definition of, 912–913
open cavity, definition of, 912
pediatric, 921
perioperative antibiotics in, 921
postoperative care following, 921–922
radical, definition of, 913
types and variations of, 372–373

MDConsult, 1167

MEDCIN, 1218–1219

Medem, 1154, 1155

Medical information, privacy and security of, **1203–1209**

Medical literature, on Internet, searching of, **1163–1174**
searches of, available sources of, 1165–1167
quality of, 1164

Medical record, computerized, 1211
electronic, architectural flaws of, 1227
"center of universe" problem and, 1228
codification of medical knowledge in, 1233–1235
effects on research, 1226
free text and, 1230
functional deficiencies of, 1228–1229
"gold standards" for, 1229
ideal system for, 1231–1236
architecture of, 1235–1236
goals of, 1232–1233
mobile platform for, 1236
input devices and, 1230
interface flaws and, 1228
new regulations concerning, 1224
software for, purchasing or leasing of, 1231
structure of, 1229–1230
update on, **1223–1236**

MEDLINE, 1146, 1165, 1166

Melkersson-Rosenthal syndrome, 363

Ménière, Prospere, 455, 497, 529, 547, 581, 622

Ménière's disease, 269–272
acute, medical treatment of, 486
age at onset of, 464
allergy and, 480, 536–537, 582–583
and HLA antigens, 504–505, 533
and migraine, 505–507
and otosclerosis, 481, 535
anticipation and, 498, 502
antihistamines in, 584, 587
as late-onset disease, 501
attack-free interval in, management of, 486–487
audiometric evaluation in, 290
audiometry in, 549–550, 551
auditory brainstem response in, 551–554
autoimmunity and, 537–538
autoimmunity tests in, 559
bilateral, 470, 471, 568, 582, 623
chemical labyrinthectomy in, 679
biological fitness and, 503
birth order effect and, 503
chemical and physical labyrinthectomy for, **675–683**
chemical perfusion of inner ear in. *See Ear, inner, chemical perfusion of.*
classification and staging of, 291
clinical features and natural history of, 468–471
computerized dynamic platform posturography in, 290
dark cells and, 520–521, 522
definition of, 287, 455, 529, 565
developmental factors in, 573
diagnosis of, 287–291
inconsistency of, primary physicians and, 459–460
multiplicity of criteria for, 460–465
routine and extended tests in, **547–563**
diet and lifestyle changes in, 586
differential diagnosis of, 482, 549
disease mapping in, 498
diuretics in, 585, 587
early-onset, 508, 509, 510
early vestibular rehabilitation in. See *Vestibular rehabilitation, early.*
electrocochleography in, 290, 552, 554–556, 630
and glycerol test in, 557
electronystagmography with calorie testing in, 550–551
endolymphatic hydrops and, 455, 472, 473, 517–519, 531–532, 566, 573–575, 622
endolymphatic sac enhancement surgery in. See *Endolymphatic sac surgery.*
epidemiology of, 459–465
problems of data analysis and, 460
etiology of, 572–575, 623–624
pathophysiology of, and pathogenesis of, **529–545**
etiopathogenesis of, 477–482, 530–538
familial, 499–501, 502
food allergies and, **581–589**
genetics and, **497–516**, 532–533
series update on, 501–503
glucose tolerance test and plasma insulin measurement in, 559
glycerol test in, and distortion-product otoacoustic emissions in, 557–558
with audiometry, 557
hearing loss in, 288, 468, 469, 570
high jugular bulb in, 525

Ménière's disease (*continued*)
history of, and clinical presentation of, **565–582**
identical disease phenotypes and, 498
imaging of temporal bone in, 559–560
immune-mediated diseases of inner ear and, 583–584
incidence of, 462–464, 499, 500, 566–567
inherited, *COCH* gene and, 508–512, 513, 533
multifactorial, 570–571
laboratory tests in, 554
labyrinthine crisis in, 458, 549
labyrinthine membrane ruptures in, 519–520
linkage analysis and, 508
malabsorption of endolymph in, 531
male/female ratio of, 464–465
mastoid in, radiographs of, 554
medical management of, 291–293, **581–589**
membranous labyrinth in, collapse of, 473
fistulae of, 473
ruptures of, 472–473
microcatheter for, 649
MicroWick for, 45–648, 649–650
natural and "induced", pathogenesis of, 618–619
natural history of, 460, 567–571
neural lesions in, 474
nitric oxide and, 535–536
nonprogressive, 470, 625
obstruction of longitudinal flow in, 474
organ of Corti and cochlear nerve and, 520
otitis media and, 534–535
overview, epidemiology, and natural history of, **455–495**
paravestibular canaliculus in vein in, 525
pathogenesis of, 529, 530, 540–541, 624
reversal of, with endolymphatic sac enhancement, **621–637**
pathology of, 471, 571–572, 623
and pathophysiology of, **517–528**
pathophysiology of, 474–477, 538–539, 575–576
peripheral lesions causing, 485
physical therapy and vestibular rehabilitation in, 586–587
pneumatization of petrous bone in, 525
progressive, 469–470, 625
endolymphatic sac enhancement in, 625–626
treatment of, 608
sensory lesions in, 474
sex distribution and, 501
sporadic, 499, 500
steroid therapy in, 584–585, 587
stria vascularis and, 520, 521
sudden-drop attacks(Tumarkin's attacks) in, 569–570
supportive and psychologic therapy in, 585–586
surgical management of, 293–294
surgical treatment of, 487–488
symptoms of, 548, 565, 570–571
pathophysiology of, 542
transtympanic gentamicin perfusion in, **287–295**
transtympanic injections for, 648–649
trauma and, 535
traveling-wave velocity test in, 558–559
treatment of, 484–488
history of, 547–548
vasopressin and, 536
vertigo in, 468–469, 569, 581
physiopathology of, 456–459
vestibular aqueduct and, 521–523
vestibular autorotation test in, 558
vestibular fibrosis in, 474
vestibular nerve section in. See Vestibular nerve section.
vestibular neurectomy in, 304, 305–308
vestibular testing in, 290
video-oculography in, 558
viral infection and, 537

Meniere's syndrome, definition of, 287
delayed-onset, 289
postinfectious, 289

Meningiomas, imaging of, 243, 1328–1329, 1347, 1354

Mentalis muscle, botulinum toxin injection in, 181–182

Mepivacaine, 41

MeSH terms, 1168–1169

Metalloproteinases, matrix, in laryngeal cancer metastasis, 990

Metrics for Technical Skills Conference, 1291
levels of curriculum building from, 1294–1295
metrics for outcomes analysis tools from, 1295
simulator systems from, 1292–1293

Microdermabrasion, for skin resurfacing, 61

Microepidermabrasion, **135–151**

clinical variations of, 147–148
contraindications to, 142–144
evolution of technology and, 148
histology and, 137–139, 140
history of, 135
indications for, 141–142, 143
particle beam resurfacing in, 136–137
patient selection for, 139–141
post-treatment protocols after, 146–147
technique of, 139–148
theory of, 135–136
treatment technique in, 144–146

Microscope, binocular operating, in neuro-otology, 231

Microsurgery, versus stereotactic radiosurgery, 353–354

Microvascular decompression syndromes, endoscopy in, 309–313

MicroWick, for Ménière's disease, 645–648, 649–650
for sudden deafness, 650–651

Middle ear, congenital anomalies of, 861, 862–863, 865
bone-anchored hearing aid in, 871–874
hearing in, 866–867
disease of, as source of threshold variation, 841–843
incidence of, 841

Migraine, and Ménière's disease, 505–507

Milia, following phenol peel, 69

Moh's micrographic surgery, for removal of skin lesions, 167–168

Mouth, angle of, botulinum toxin injection in, 180–181
incisionless reanimation surgery of, 436–437, 438, 439, 440

Mucosal shunt procedures, following total laryngectomy, 1074

Myocutaneous flaps, in surgery of lateral skull base, 429–431

N

Nasolabial fold, botulinum toxin injection in, 179

Nasopharyngoscopy, and laryngology, efficacy of telemedicine in, 1271–1272

National Institutes of Health, Web site, 1166

National Library of Medicine, databases of, 1165

Neck, anatomy of, 182
platysma and rhytids of, botulinum toxin injection in, 182–183

Nerve(s). See also specific nerves.
conservation of, in surgery of skull base, **413–426**
facial. See *Facial nerve.*
trigeminal, facial, cochlear or vestibular, endoscopy in surgery of, 303–309

Nervus intermedius, 660

Neurectomy, vestibular. See *Vestibular nerve section.*

Neuro-otologic conditions, diagnostic imaging in, **239–253**
general imaging principles in, 240–241

Neuro-otologic surgery, endoscopy in, **297–323**

Neuro-otology, areas of advancement in, 229
audiology and, 230–231
diagnostic studies and, 229–231
equipment in, 231–232
history of, personal perspective on, **227–238**
new frontiers in, 233–236
radiographic studies and, 229–230
surgical technique in, 232

Neurofibromatosis type 2, hearing loss in, 827
tumors in, imaging of, 243, 1327–1328

Neurosurgery, robotic, 1305

Nitric oxide, and Ménière's disease, 535–536

Nitrogen, liquid, delivery of, for cryosurgery, 154–155
complications of, 156

Norrie's disease, deafness in, 826–827

Nose, flaring of, botulinum toxin injection in, 179

Nystagmus, otokinetic, and optokinetic
afternystagmus, in children, 772–774
spontaneous, observation in children, 769

O

Octyl-2-cyanoacrylate, 105–114
advantages of, 105
clinical outcomes using, 105–106
disadvantages of, 106

Octyl-2-cyanoacrylate (*continued*)
patient selection for use of, 106
postoperative care following use of, 114, 115, 116
technique of application of, 107–113
wounds appropriate for, 106–107

Oculomotor testing, in children, 770

Ohio State University, experience with surgical simulation, **1283–1288**

OLDMEDLINE, 1165

Orbicularis, and crow's feet, botulinum toxin injection in, 178–179

Organ of Corti, and Ménière's disease, 520

Oropharyngeal cancer, radiotherapy and, carboplatin and 5-fluorouracil in, 1038

Oropharyngeal swallow efficiency, 1102

Orthopedics, robotic surgery in, 1308–1309

Ossicular anomalies, congenital stapes footplate fixation with, 868–869

Ossicular chain, anomalies of, 863
with mobile footplate, 869
development of, 856

Ossicular fixation, 857

Otitis media, acute, in children, treatment recommendations in, 800–801
recurrent, in children, treatment recommendations in, 801–802
chronic, and Ménière's disease, endolymphatic sac surgery and, 596–597
surgical management of, **911–924**
definitions of, 794
in children, complications of, 803
infectious factors in, 798–799
medical and surgical management of, **793–807**
prevention of, 799–800
surgical therapy for, 796–798
treatment of, costs of, 794
options for, 793
outcomes of, 795–798
recommendations for, 800–803
Ménière's disease and, 534–535
natural history of, 795
recurrent, auditory processing disorders and, 927–928
risk factors for, 795–796
vertigo in, 267–268
with effusion, in children, treatment recommendations in, 802–803

Otoacoustic emissions, detection of, in children, 711
distortion-product, detection of, in children, 713–715, 722
transient-evoked, detection of, in children, 711–713

Otolaryngologic surgery, robotic, 1308

Otolaryngologist(s), in management of hearing loss in infants and children, **743–754**
in United States, distribution of, 1264, 1266

Otolaryngology, rehabilitative, efficacy of telemedicine in, 1272
telemedicine in, 1269–1270

Otologists, of twentieth century, 227–229

Otosclerosis, Ménière's disease and, 481, 535

Otoscopy, video, efficacy of telemedicine in, 1272

Oval window, aplasia/severe dysplasia of, 870–871
development of, 857

P

Paclitaxel, trials of, in laryngeal preservation, 1031–1032

Papillomavirus, human, cancer development and, 986

Particle beam resurfacing, in microepidermabrasion, 136–137

Patient(s), traditional encounters with Internet, 1144–1145

Patient-physician interactions, in Internet, 1145–1146

Patient records, paper, 1227

Pectoralis major myocutaneous flap, pedicled, following laryngopharyngectomy, 1093

Peels, chemical. See Chemical peels.

Pendred syndrome, deafness in, 822–823

Petrous apex, diagnostic imaging of, 248–249, 1340, 1343, 1344
drainage procedures for, 374
endoscopes during surgery of, 314

Petrous apicitis, 1343–1346

Petrous bone, anatomy of, 370–371
pneumatization of, in Ménière's disease, 525

Petrous carotid aneurysms, imaging of, 1346, 1347

Pharyngeal voice production, physiology and physics of, 1075–1076

Phenol, for skin resurfacing, 56, 58

Phenol peels, 65–71
complications of, 69–70
indications for, 66
mechanism of action of, 66–67
postpeel care in, 68–69
preparation for, 67–68
pretreatment for, 67
technique of, 68

Photoaging, histologic effects of, 57–58

Physical therapy, and vestibular rehabilitation, in Ménière's disease, 586–587

Physician(s), Internet resources for, 1146–1147
marketing of practice, goals of, 1150–1151
on Internet, **1149–1161**
medical practice Web site for, 1145–1146, 1153

Physician-patient relationship, and Internet, **1143–1148**
online, 1159–1160

PICO system, categories in, 1168

Plasma insulin, measurement of, and glucose tolerance test, in Ménière's disease, 559

Plastic surgery, of face, office-based procedures in, **1–220**

Polymethylmethacrylate, for soft tissue augmentation, 83

Polytetrafluoroethylene, expanded, for augmentation of lips, 99

Positron emission tomography, 1326
for organ presentation strategies, 1039–1040
in laryngeal cancer, 972–973
prior to laryngopharyngectomy, 1089–1090

Posterior fossa, lesions of, imaging of, 1331–1335
treatment of, 234–235

Postioning and positional (gaze-holding) tests, in children, 770

Posturography, platform, for assessment of children, 774–775

PREMEDLINE, 1165

Pressure therapy, for treatment of keloid, 216–217

Proto-oncogene amplification, in laryngeal cancer, 989

PubMed, 1165–1166, 1167
Clinical Queries of, 1171
Cubby of, 1172
features of, 1171–1172
LinkOut of, 1171–1172

Pulsatile tinnitus, subjective, evaluation of, 250

Pursuit tracking, in children, 770–772

Pyriform sinus tumors, medial, partial laryngopharyngectomy for, 1091

R

Radial forearm free flap, following laryngopharyngectomy, 1094–1095

Radiotherapy, and chemotherapy, sequential, in laryngeal cancer, 1072
carboplatin and 5-fluorouracil, in oropharyngeal cancer, 1038
definitive, for squamous carcinoma of larynx, **1003–1023**
for early glottic laryngeal cancer, 1005–1009, 1016, 1018, 1019–1020
for subglottic laryngeal cancer, 1014–1015
for supraglottic laryngeal cancer, 1009–1014
for treatment of keloid, 215–216
in hypopharyngeal cancers, 1088–1089
in laryngeal preservation strategies, 1029–1032
intensity-modulated, 1016–1020
primary, voice deficits following, 1110–1111
robotic, 1306–1308
three-dimensional conformal, 1016–1018

Resoplast, for augmentation of lips, 95

Restylane, for augmentation of lips, 94, 95

Retinoic acid, for skin resurfacing, 61

Rhinoplasty, as exacting and difficult procedure, 1–2
candidate rejection for, 10–11
consent forms for, 7–9
initial encounter for, 2–10
interview techniques for, 3–5
laboratory evaluation for, 23–27
patient education for, 5–7, 10
patient evaluation for, physical aspects of, 11–12
photographic documentation for, 18–23
physical evaluation of, 11–12
potential patient problems associated with, 7
preoperative, **1–27**
preoperative facial photographs for, 5
supportive preoperative evaluation for, 18–27

Rhytidectomy, for laser skin resurfacing, 131

Robodoc, 1308–1309

Robot, active, 1304
passive, 1305
semiactive, 1304–1305
surgical, 1304

Robotic surgery, **1303–1317**
acceptance of, 1315
current applications of, 1305–1312
definitions associated with, 1304–1305

Ropivacaine, 42

Royamid, for augmentation of lips, 99

S

Saccades, in children, 774

Scarring, following laser skin resurfacing, 130–131
following phenol peel, 70–71
hypertrophic, and keloid, clinical differentiation of, 208
following trichloroacetic acid peel, 64–65

Schwannoma(s), facial, imaging of, 244, 1336–1338
labyrinthine, imaging of, 1359
of cranial nerves, imaging of, 244, 1329–1331
vestibular. See *Acoustic neuroma(s)*.

Scleral show, following phenol peel, 70

Semicircular canal, posterior, surgery on, 233

Shea, John, 228

Silicone, for soft tissue augmentation, 82

Single-citation matcher, 1171

Sinus Surgery Simulator, Endoscopic. See *Endoscopic Sinus Surgery Simulator*.

Skin, depigmentation of, following phenol peel, 70

Skin biopsy, 156–162
choosing technique for, 157–158
preparation for, 158–159
punch biopsy for, 160–162
shave biopsy for, 159–160
shave excision for, 162
snip excision for, 159

Skin closure, in outpatient setting, cyanoacrylate tissue adhesives for, **103–118**
subcutaneous sutures for, 103
suture care following, 103

Skin grafts, split-thickness, following laryngopharyngectomy, 1093

Skin lesions, removal of, cryosurgery for, 153–156
curettage and electrodesiccation for, 163–166
ellipse for, 166–167
Moh's micrographic surgery for, 167–168
skin biopsy for, 156–162
techniques in, **153–170**

Skin resurfacing, in photoaging, 57–58
laser. See *Laser skin resurfacing*.
techniques of, 59–61

Skull base, lateral, surgery of, endoscopy in, 313–318
flap reconstruction in, history of, 427–429
free flaps in, 431–434
myocutaneous flaps in, 429–431
with facial incisionless reanimation surgery, reconstruction following, **427–446**
lesions of, treatment of, 235
surgery of, monitoring during, 414–415
neural conservation in, **413–426**
transpetrosal surgical approaches to, 375–389
anterior petrosectomy, 386
combined, 388–389
history of, 376–377
inferior, 386–388

infratemporal fossa, 386–388
Kawase's, 386
middle fossa, expanded, 385
middle fossa-transpetrous, 386
posterior, lateral, 379
retrosigmoid, 379, 380
posterior petrosectomy, 381
preoperative planning for, 377
presigmoid, 381
retrolabyrinthine, 381
superior, 383, 384–385
transcochlear, 382
translabyrinthine, 381–382
expanded, 382
partial, 382
transotic, 383
zoned, 377–379
tumors of, carotid artery in, 413–414
involving jugular foramen, 415–416

Sodium bicarbonate, and sodium chloride, for microepidermabrasion, 149–150

Sodium chloride, and sodium bicarbonate, for microepidermabrasion, 149–150

Soft tissue fillers, injectable, collagen and, **73–85**

Softform tubes, in augmentation of lips, 99–100

Sound, transmission of, molecular genetic approaches to, 279–280

Speech recognition measures, supratheshold, with reinforcement in children, 720

Speech therapy, swallowing and, after laryngeal cancer treatment, **1101–1119**

Stapes, development of, 857
footplate fixation, congenital, 861–868
with ossicular anomalies, 868–869

Stereotactic radiosurgery, advances in, 347–348
after failed microsurgery, 354
complications of, 351–353
failed, microsurgery after, 354
future considerations in, 355
in acoustic neuroma, 401–402
in acoustic tumors, **345–357**
indications for, 348
microsurgery versus, 353–354
results of, 348–351
technique of, 346–347

Steroid therapy, in Ménière's disease, 584–585, 587

Steroids, intralesional, for treatment of keloid, 214–215

Stickler syndrome, hearing loss in, 828

Stria vascularis, and Ménière's disease, 520, 521

Stroboscopy, laryngeal, 949

Stroke, delayed, in carotid artery occlusion, 413–414

Structured documentation, **1211–1221**
benefits of structure in, 1215–1216
choosing of, 1219–1220
controlled vocabularies in, 1212–1215
examples of, 1217–1219
future trends in, 1219
knowledge-based relationships in, 1204
overview of, 1212, 1213
trade-offs in, 1216–1217

Surgery, general, robotic, 1309–1311

Surgical simulation, update on, **1283–1288**

Swallow efficiency, oropharyngeal, 1102

Swallowing, and speech therapy, after laryngeal cancer treatment, **1101–1119**
and voice, following minimally invasive treatment, 1103–1105
disordered, 1102–1103
evaluation of, 1103
following endoscopic resection of larynx, 1105
following laryngeal conservation surgery, 1106
following laryngeal preservation strategies, 1113
following primary radiation therapy, 1111–1112
laryngeal cancer and, 1102
normal phases of, 1102

Swallowing therapy, following laryngeal conservation surgery, 1106–1107
following laryngeal preservation strategies, 1113–1114
following primary radiation therapy, 1112
following total laryngectomy with transesophageal conduit, 1110

Systemized Nomenclature for Human and Veterinary Medicine, 1217–1218

T

Tattoo, cosmetic, for augmentation of lips, 100

Taxanes, trials of, in laryngeal preservation, 1031–1032

Telemanipulators, master-slave. See *Master-slave telemanipulators.*

Telemedicine, bandwidth of, progressive expansion of, 1264, 1265
clinical efficacy studies of, 1271
cost of, 1275–1277
efficacy of, in nasopharyngoscopy and laryngology, 1271–1272
in rehabilitative otolaryngology, 1272
in video otoscopy, 1272
equipment for, 1274–1275, 1276, 1277
general concepts in, 1267–1269
history of, 1264
in otolaryngology, **1263–1281**
legal issues and, 1273–1274, 1275
licensure and credentialing for, 1266, 1273, 1274
master-slave telemanipulators in, 1315
reimbursement for, 1272–1273
success in, 1264–1267
teleproctored/telementored surgery and, 1278–1279

Teleproctored/telementored surgery, telemedicine and, 1278–1279

Temporal bone, cerebrospinal fluid leaks of, imaging in, 247, 1340, 1341, 1342–1343
dissection simulator, 1285, 1286
imaging of, 247, 249, 1336
in Ménière's disease, 559–560
malignancy of, **407–412**
clinical and radiographic examination in, 408–409
differential diagnosis of, 408
epidemiology of, 407–408
site of origin of, 407
treatment of, 409–410
long-term results of, 410–411
postoperative complications of, 410
petrous portion of, 370–371
resection of, 374–375, 376

Tetracaine, 38

Tetracaine-adrenaline-cocaine, 39

Thigh, lateral, free flap of, following laryngopharyngectomy, 1095–1096

Thoracic surgery, robotic, 1311–1312

Tinnitus, microvascular decompression for, 309–310, 311, 312

Tissue adhesives, alternative, 114–117
cyanoacrylate. See *Cyanoacrylate tissue adhesives.*

Tissue transfer, free microvascular, following total laryngopharyngectomy, 1087

Tobacco smoke, mutagenic compounds in, 985

Tracheoesophageal conduit, total laryngectomy with. See *Laryngectomy, total, with tracheoesophageal conduit.*

Tracheoesophageal puncture, and esophageal speech, compared, following total laryngectomy, 1075–1076
and fistula, timing of creation of, 1076–1077
closure of, 1083
primary, technique of, 1077–1078
secondary, technique of, 1078–1079
technical aspects of, 1076–1081
voice prosthesis in, 1088
averting long-term failure of, 1081–1083
fitting and maintaining of, 1079–1081

Transconjunctival blepharoplasty, for laser skin resurfacing, 131

Transesophageal conduit, total laryngectomy with, swallowing therapy following, 1110

Transpetrosal surgery techniques, **369–393**
nomenclature schema in, 369–370

Transpetrosal surgical approaches to skull base. See *Skull base, transpetrosal surgical approaches to.*

Traveling-wave velocity test, in Ménière's disease, 558–559

Treacher Collins syndrome, hearing loss in, 828

Trichloroacetic acid peels, 61–65
complications of, 64–65
indications for, 62
postpeel care and, 64
pretreatment for, 62–63
technique of, 63–64

Trigeminal nerve, facial, cochlear, or vestibular nerves, endoscopy in surgery of, 303–309

Trigeminal neuralgia, microvascular decompression for, 310–313

Tumor suppressor gene inactivation, and allelic loss, in laryngeal cancer, 987–989

Tympanomastoidectomy, canal wall-down, 372, 373
canal wall-up, 372, 373

Tympanometry, in children, 715–716

Tympanoplasty, definition of, 912
indications for, 915
mastoidectomy during, indications for, 915

U

Urban, Jack, 232, 236

Urology, robotic surgery in, 1309

Usher syndrome, hearing loss in, 825

V

Vascular lesions, of cerebellopontine angle, imaging of, 245
of temporal bone, imaging of, 249

Vasopressin, and Ménière's disease, 536

Vein, in paravestibular canaliculus, in Ménière's disease, 524–525

Verrucous carcinoma, 1015

Vertigo, benign paroxysmal positional, 268–269
central lesions causing, 484
in acute suppurative otitis media, 268
in cholesteatoma, 268
in endolymphatic hydrops, 269–272
in eustachian tube dysfunction, 268
in foreign bodies in external ear, 267
in Ménière's disease, 455, 497, 529, 547, 581, 622
in otitis media with effusion, 267–268
in vestibular neuritis, 269
inner ear causes of, 268–269
medical management of, 233–234
surgery for, endolymphatic sac procedure in, 233
vestibular nerve section in, 233
vascular causes of, 269

Vestibular aqueduct, and Ménière's disease, 521–523
imaging of, 1356, 1358

Vestibular autorotation test, in Ménière's disease, 558

Vestibular-evoked myogenic potential, pediatric, 775–776

Vestibular examination, pediatric, 761–769
assessment of static visual acuity in, 762
assessment of vestibular autorotation in, 764
examination of head-motion nystagmus in, 763–764
head-impulse test in, 764
passive whole-body (en bloc) rotation in, 764–768
sinusoidal oscillation test in, 765
suppression of angular vestibulo-ocular reflex in, 768
velocity step test in, 765–767, 768

Vestibular function, evaluation of, in young children, **755–780**

Vestibular laboratory, pediatric, testing in, 758–761

Vestibular loss, and hearing loss, in young children, 756
peripheral, in young children, differential diagnosis of, 758
history taking in, 757
physical examination in, 757–758
presentation of, 756–757

Vestibular nerve(s), 659
inferior, 659
preservation of function of, in acoustic neuroma surgeryy, 421–424
trigeminal, facial, or cochlear nerves, endoscopy in surgery of, 303–309

Vestibular nerve section, **655–673**
complications of, 670–671
contraindications to, 661
historical perspective on, 655–660
indications for, 660–661
patient selection for, 660–661
postoperative care following, 668–669
results of, 669–670
surgical technique of, middle fossa approach for, 662, 663, 664
posterior fossa approach for, 663–665
retrolabyrinthine approach for, 665–666, 667, 669
retrolabyrinthine-retrosigmoid combined approach for, 668, 669, 670
retrosigmoid-internal auditory canal approach for, 666–668, 669–670

Vestibular neurectomy, endoscopic, 304–308
advantages and limitations of, 308–309

Vestibular neuritis, vertigo in, 269

Vestibular rehabilitation, early, in Ménière's disease, **685–692**
adaptive equipment and, 689
environmental modifications and, 690
fluctuations in functional ability and, 688–690
future considerations in, 692
patient education for, 686–687
patient selection for, 685
physical therapy in, examination for, 687–688
preventive strategies and, 690–691
self-empowerment and, 691
side effects of attacks and, 689
treatment options for, explanation for, 687
physical therapy and, in Ménière's disease, 586–587

Vestibular schwannomas. See *Acoustic neuroma(s)*.

Video-oculography, binocular, in children, 761
in Ménière's disease, 558

Viral infection, and Ménière's disease, 537

Virtual binoculars, 1285, 1286

Virtual reality training systems, 1284

Visceral transposition flaps, following laryngopharyngectomy, 1096–1097

Vocal cords, functional divisions of, 1101–1102

Voice, assessment of, 1102
deficits in, following endoscopic resection of larynx, 1103
following laryngeal conservation surgery, 1105
following laryngeal preservation strategies, 1112–1113
following primary radiation therapy, 1110–1111
following total laryngectomy with tracheoesophageal conduit, 1107–1108
pharyngeal production of, physiology and physics of, 1075–1076
production of, 1101–1102
swallowing and, following minimally invasive treatment, 1103–1105

Voice prosthesis, in tracheoesophageal puncture, 1081–1083, 1088

Voice therapy, following endoscopic resection of larynx, 1104
following laryngeal conservation surgery, 1105–1106
following laryngeal preservation strategies, 1113
following primary radiation therapy, 1111
following total laryngectomy with tracheoesophageal conduit, 1108–1109

W

Waardenburg syndrome, hearing loss in, 824–825

Web, advertising on, 1151–1153

Web browser, on exercise equipment, 1152

Web site, creation of, approach to, budget and, 1153–1157
effective, Web style for, 1157–1159
for facial plastic surgery practice, 1157, 1158
medical content of, 1159
medical practice, for physician, 1145–1146, 1153
promotion of, and maintenance of, 1160–1161

Z

ZEUS Robotic Surgical System, 1304, 1306, 1311

Zyderm, 74–77

Zyplast, 74–77